Wang Gangzheng, Sun Chengyuan, Xie Bojun, Wang Tao, Liu Hongwei, Chen Xianglian, Huang Qiuju, Zhang Chenghua, Li Taihui, Deng Wangqiu
Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou, China.
State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Front Nutr. 2022 Nov 2;9:1038740. doi: 10.3389/fnut.2022.1038740. eCollection 2022.
Obesity has caused serious health and economic problems in the world. is a high-value macrofungus with broad application potential in the food and bio-medicine industry. This current study aimed to estimate the role of lipid-lowering compound formula (CGLC) in regulating fat and lipid accumulation, gut microbiota balance, short-chain fatty acid (SCFA) contents, and expression levels of genes involved in fat and lipid metabolism in high-fat diet (HFD) mice. The results showed that CGLC intervention markedly reduced body weights and fat accumulation in HFD mice, improved glucose tolerance and blood lipid levels, and decreased lipid droplet accumulation and fat vacuole levels in the liver. CGLC decreased the ratio of Firmicutes and Bacteroidetes and increased the relative abundances of () and (). In addition, CGLC treatment significantly promoted the production of SCFAs and regulated the relative expression levels of genes involved in fat and lipid metabolism in liver. Association analysis showed that several species of and most of SCFAs were significantly associated with serum lipid indicators. These results suggested that CGLC is a novel candidate formulation for treating obesity and non-alcohol fatty liver by regulating gut microbiota, SCFAs, and genes involved in fat and lipid metabolism.
肥胖已在全球范围内引发了严重的健康和经济问题。[某种东西]是一种具有高价值的大型真菌,在食品和生物医药行业具有广泛的应用潜力。本研究旨在评估降脂复方配方(CGLC)在调节高脂饮食(HFD)小鼠脂肪和脂质积累、肠道微生物群平衡、短链脂肪酸(SCFA)含量以及参与脂肪和脂质代谢的基因表达水平方面的作用。结果表明,CGLC干预显著降低了HFD小鼠的体重和脂肪积累,改善了葡萄糖耐量和血脂水平,并减少了肝脏中的脂滴积累和脂肪空泡水平。CGLC降低了厚壁菌门和拟杆菌门的比例,并增加了[某些菌属]和[另一些菌属]的相对丰度。此外,CGLC处理显著促进了SCFAs的产生,并调节了肝脏中参与脂肪和脂质代谢的基因的相对表达水平。关联分析表明,几种[菌属]和大多数SCFAs与血脂指标显著相关。这些结果表明,CGLC是一种通过调节肠道微生物群、SCFAs以及参与脂肪和脂质代谢的基因来治疗肥胖和非酒精性脂肪肝的新型候选配方。